Phase 2 N=24 An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
Dermatomyositis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 7; 13; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=300 A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Syndrome
Primary: Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness. — -0.7; -0.5; -0.4 units on a scale
Phase 2 N=86 A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
Parkinson Disease · Cognitive Dysfunction
Primary: Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score — 2.0; 2.0 score on a scale — p=0.9934
Phase 2 N=153 Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
Type 2 Diabetes Treated With Insulin
Primary: Change in HbA1c — -0.20; -0.53; -0.31 % of glycated haemoglobin — p=0.0039
Phase 2 N=159 Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
PTSD
Primary: Newly Treatment Emergent Adverse Events — 37; 20; 14 Participants
Phase 2 N=15 Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Advanced Solid Tumor · IDH1 Mutation · Glioma
Primary: Best Overall Response — 1; 6 Participants
Phase 2 N=42 Karolinska Interventional Study of Mammograhic Density (Karisma-1)
Breast Cancer · Mammographic Density
Primary: Mammographic Breast Density — -3.3; -2.5 percentage of breast area
Phase 2 N=16 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Progression Free Survival (PFS) — 255.921 days to progression
Phase 2 N=18 Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Presbyopia
Primary: Proportion of Subjects With a >=15 Letter Gain Without a < 5 Letter Loss in Near Visual Acuity — 15; 15; 16 Participants
Phase 2 N=56 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Phase 2 N=355 Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
Allergic Rhinitis Due to House Dust Mite
Primary: Change From Baseline to the End-of-treatment Period in the Area Under the Curve of the Rhinitis Total Symptom Score Recorded During 4 Hours (0-4h) of the Allergen…
Phase 2 N=698 A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 77; 86; 81; 72 Participants
Phase 2 N=20 Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants
Phase 2 N=1,079 A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
Cervical Intraepithelial Neoplasia
Primary: Number of Participants Reporting Grade 3 Solicited Administration Site Events After Vaccine Dose 1 — 11; 12; 6; 2 Participants
Phase 2 N=31 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Pancreatic Cancer
Primary: CD8+ T Cell Density in Tumor Tissue — 5.4 log (cells per mm^2)